For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 9,941 | 4,266* | 10,085 | 9,389 |
| General and administrative | 4,971 | 3,604* | 3,831 | 4,333 |
| Total operating expenses | 14,912 | 7,870 | 13,916 | 13,722 |
| Loss from operations | -14,912 | -7,870* | -13,916 | -13,722 |
| Interest income, net | 1,696 | 1,275* | 2,101 | 1,407 |
| Other income (expense), net | 4 | -17* | -2 | -7 |
| Interest expense | - | 0* | 0 | 0 |
| Total other income, net | 1,700 | 1,257* | 2,099 | 1,400 |
| Loss before income taxes | -13,212 | -6,614* | -11,817 | -12,322 |
| Income tax benefit | -20 | -10* | -15 | -21 |
| Net loss | -13,192 | -6,604 | -11,802 | -12,301 |
| Basic EPS | -0.09 | -0.051 | -0.08 | -0.09 |
| Diluted EPS | -0.09 | -0.051 | -0.08 | -0.09 |
| Basic Average Shares | 145,592,901 | 128,786,217 | 145,104,986 | 130,350,391 |
| Diluted Average Shares | 145,592,901 | 128,786,217 | 145,104,986 | 130,350,391 |
Trevi Therapeutics, Inc. (TRVI)
Trevi Therapeutics, Inc. (TRVI)